Literature DB >> 3766710

Outpatient rehabilitation for chronic neuromuscular diseases.

S J Koch, D E Arego, B Bowser.   

Abstract

Cost-conscious outpatient rehabilitation of 210 patients in a neuromuscular disease clinic was examined. The patients followed over a one-year period included: Duchenne Muscular Dystrophy, [50], Charcot-Marie-Tooth [42], Limb-Girdle Dystrophy [37], Spinal Muscular Atrophies [28], "Congenital" Myopathies [12], Friedreich's Ataxia [7], Polymyositis [7] and other related diseases. The 210 patients were profiled by age, sex, family history, and age at onset of symptoms. The rehabilitation of each patient was examined for ancillary service utilization such as pulmonary [11%], orthopedic [10%], and social services consultations [43%], formal occupational [7%] and physical therapy sessions [6%]. Rehabilitation costs were computed for each patient and each disease. "Rehabilitation Costs" included: equipment, laboratory fees, physician fees, building use, medications, travel, and P.T., O.T. and social service charges. Equipment expenditures were the major portion of rehabilitation, determined to be 70% of the annual costs. Because equipment was determined to be the overwhelming "rehabilitation" expense, the types of equipment prescribed for each disease were also defined. Laboratory testing was the next most costly category, resulting in 11% of the overall cost. Physician fees were determined to be only 8% of annual rehabilitation costs. The total mean per capita cost of outpatient rehabilitation was $750 per year, with a range of from $200 per year for Myotonic Dystrophy to $1200 per year for Duchenne Muscular Dystrophy. This study indicates that annual per capita "Rehabilitation Costs" in an outpatient neuromuscular disease clinic are surprisingly inexpensive when one considers the extent of disability in these diseases.

Entities:  

Mesh:

Year:  1986        PMID: 3766710

Source DB:  PubMed          Journal:  Am J Phys Med        ISSN: 0002-9491


  2 in total

1.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy.

Authors:  Min Yang; Hiroyuki Awano; Satoru Tanaka; Walter Toro; Su Zhang; Omar Dabbous; Ataru Igarashi
Journal:  Adv Ther       Date:  2022-03-20       Impact factor: 4.070

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.